Aadi Bioscience, Inc. (NASDAQ: AADI), a US-based commercial-stage biopharmaceutical company, announced on Friday that it has named Scott Giacobello as its interim chief executive officer and president in addition to his current responsibilities.

Presently, Giacobello serves as the company's chief financial officer. He replaces Brendan Delaney, who has resigned for personal reasons from his position as chief executive officer, president, and member of the company's board of directors.

Giacobello has played a key role in the buildout of US operations and commercial readiness in his role as CFO at GW Pharmaceuticals. He previously held the position of the CFO of Chase Pharmaceuticals prior to its acquisition by Allergan, where he served in executive roles in corporate finance and global research and development.